L.D. EGAMBERDIEVA, E.I. ANTIPOVA, R.I. GABIDULLINA

 Kazan State Medical University, Kazan

Contact details:

Egamberdieva L.D. — PhD (Medicine), Associate Professor at the Department of Obstetrics and Gynecology named after Prof. V.S. Gruzdev

Address: 49 Butlerov St., 420012 Kazan, Russian Federation, tel.: +7-904-765-22-62, e-mail: lutsia1@yandex.ru

Menopausal hormone therapy (MHT) remains the most effective treatment for vasomotor symptoms of menopause, genitourinary syndrome, and the prevention of postmenopausal osteoporosis. Liver plays a key role in the sex hormones metabolism, making the issue of MHT hepatobiliary safety critically important when choosing therapy.

The purpose — to summarize current literature data on the impact of menopausal hormone therapy on the liver and possible adverse effects.

Material and methods. A systematic search and analysis of publications in international peer-reviewed journals indexed in PubMed, JAMA, EMBASE, and Google Scholar, as well as relevant national scientific journals and clinical guidelines from 2013 to 2026.

Results. Modern data have fundamentally changed the view on the hepatobiliary safety of MHT. Oral forms are indicated for compensated chronic liver diseases, metabolic syndrome, including non-alcoholic fatty liver disease. Transdermal MHT is the drug of choice for primary biliary cholangitis and can be used in non-alcoholic fatty liver disease.

Conclusion. An individual approach, based on assessing liver function before prescription and choosing an appropriate administration route, makes MHT a safe and effective method for the majority of peri- and postmenopausal women.

Key words: menopausal hormone therapy, hepatobiliary safety, postmenopause

REFERENCES

1. Menopauza i klimaktericheskoye sostoyaniye u zhenshchiny: MKB 10: N95, N95.2, N95.3, N95.8, N95: klinicheskiye rekomendatsii. Ministerstvo Zdravookhraneniya Rossiyskoy Federatsii, Rossiyskoye obshchestvo akusherov-ginekologov [Menopause and climacteric condition in women: ICD 10: N95, N95.2, N95.3, N95.8, N95: clinical guidelines. Ministry of Health of the Russian Federation, Russian Society of Obstetricians and Gynecologists]. Moscow, 2025. Pp. 6-40, available at: https://cr.minzdrav.gov.ru/view-cr/117_3 (accessed on: 22.05.2020).
2. Krasnopol’skiy V.I., Zaydiyeva Ya.Z. Farmakologicheskiye i klinicheskiye aspekty menopauzal’noy gormonoterapii [Pharmacological and clinical aspects of menopausal hormone therapy]. Moscow, 2016. P. 39.
3. Cazzagon N., Gambato M., Brunetto M.R., Villa E., Burra P., Floreani A. Sex hormones and the liver: implications for disease progression and hormonal therapy. Liver Int, 2026, vol. 46 (2), p. e70509. DOI: 10.1111/liv.70509
4. Devarbhavi H., Asrani S.K., Arab J.P., Nartey Y.A., Pose E., Kamath P.S. Global burden of liver disease: 2023 update. J. Hepatol, 2023, vol. 79, pp. 516–537. DOI: 4.10.1016/j.jhep.2023.03.017
5. Buyeverov A.O., Tapil’skaya N.I. The influence of menopausal hormone therapy on the condition of the liver and biliary tract. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2025, vol. 35, no. 3, pp. 104–113 (in Russ.). DOI: 5.10.22416/1382-4376-2025-35-3-104-113
6. Georgieva M., Xenodochidis C., Krasteva N. Old age as a risk factor for liver diseases: Modern therapeutic approaches. Exp. Gerontol, 2023, vol. 184, p. 112334. DOI: 10.1016/j.exger.2023.112334
7. Ou Y.J., Lee J.I., Huang S.P., Chen S.C., Geng J.H., Su C.H. Association between menopause, postmenopausal hormone therapy and metabolic syndrome. J. Clin. Med, 2023, vol. 12 (13), p. 4435. DOI: 10.3390/jcm12134435
8. Lin Z., Sun L. Research advances in the therapy of metabolic syndrome. Front. Pharmacol, 2024, vol. 15. 1364881. DOI: 8.10.3389/fphar.2024.1364881
9. Quek J., Chan K.E., Wong Z.Y., Tan C., Tan B., Lim W.H. et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol, 2023, vol. 8 (1), pp. 20–30. DOI: 9.10.1016/S2468-1253(22)00317-X
10. Shlyakhto Ye.V., Sukhikh G.T., Serov V.N. et al. Russian criteria for the acceptability of prescribing menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Consensus document of the Russian Society of Cardiology, Russian Society of Obstetricians and Gynecologists, Russian Association of Endocrinologists, Eurasian Association of Therapists, Association of Phlebologists of Russia. Kardiologiya, 2023, vol. 63, no. 10, pp. 9 (in Russ.). DOI: 10.10.18087/ cardio.2023.10.n2561
11. Ivashkin V.T., Drapkina O.M., Mayevskaya M.V., Raykhel’son K.L., Okovityy S.V., Zharkova M.S. Clinical guidelines for non-alcoholic fatty liver disease. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2025, vol. 35, no. 1, pp. 94–152 (in Russ.). DOI: 11.10.22416/1382-4376-2025-35-1-94-152
12. Godoy-Matos A.F., Silva Júnior W.S., Valerio C.M. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol. Metabolic Syndrome, 2020, vol. 12, p. 60. DOI: 12. 10.1186/s13098-020-00570-y
13. Dong J., Dennis K.M.J.H., Venkatakrishnan R., Hodson L., Tomlinson J.W. The impact of estrogen deficiency on liver metabolism: implications for hormone replacement therapy. Endocrine Rev, 2025, vol. 46 (6), pp. 790–809. DOI: 10.1210/endrev/bnaf018
14. Le M.H., Yeo Y.H., Zou B., Barnet S., Henry L., Cheung R. et al. Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach. Clin. Mol. Hepatol, 2022, vol. 28 (4), pp. 841–850. DOI: 14. 10.3350/cmh.2022.0239
15. Jancova P., Ismail K., Vistejnova L. Relationship between MASLD and women’s health: A review. Womens Health (Lond), 2025, vol. 21. 17455057251376883. DOI: 10.1177/17455057251376883
16. Eng P.C., Forlano R., Tan T., Manousou P., Dhillo W.S., Izzi-Engbeaya C. Non-alcoholic fatty liver disease in women — current knowledge and emerging concepts. JHEP Reports, 2023, vol. 5 (10), p. 100835. DOI: 16.10.1016/j.jhepr.2023.100835
17. DiStefano J.K. NAFLD and NASH in postmenopausal women: Implications for diagnosis and treatment. Endocrinology, 2020, vol. 161 (10). Art. bqaa134. DOI: 17.10.1210/17. HYPERLINK «https://doi.org/10.1210/endocr/bqaa13418
18. Opoku A.A., Abushama M., Konje J.C. Obesity and menopause. Best Pract. Res. Clin. Obstet. Gynaecol, 2023, vol. 88, p. 102348. DOI: 18.10.1016/j.bpobgyn.2023.102348
19. Montagna D.R., Todero M.F., Postma G.C., Trigo R., Bernal A., Bustuoabad O. et al. Resistance against the development of diethylnitrosamine-induced hepatocellular carcinoma in female C3H mice: an experimental model. Exp. Animals, 2024, vol. 73 (4), pp. 399–411. DOI: 19.10.1538/expanim.23-0149
20. Xu L., Yuan Y., Che Z., Tan X., Wu B., Wang C. et al. The hepatoprotective and hepatotoxic roles of sex and sex-related hormones. Front. Immunol, 2022, vol. 13, p. 939631. DOI: 20.10.3389/fimmu.2022.939631
21. Della Torre S. Non-alcoholic fatty liver disease as a canonical example of metabolic inflammatory-based liver disease showing a sex-specific prevalence: Relevance of estrogen signaling. Front. Endocrinol, 2020, vol. 11, pp. 572490. DOI: 21.10.3389/fendo.2020.572490
22. Weiskirchen R., Lonardo A. Sex hormones and metabolic dysfunction-associated steatotic liver disease. Int. J. Mol. Sci, 2025, vol. 26 (19), pp. 9594. DOI: 10.3390/ijms26199594
23. Wang J., Wu A.H., Stanczyk F.Z. et al. Associations between reproductive and hormone-related factors and risk of nonalcoholic fatty liver disease in a multiethnic population. Clin. Gastroenterol. Hepatol, 2021, vol. 19 (6), pp. 1258–1266. DOI: 10.1016/j.cgh.2020.08.012
24. Kim S.E., Min J.S., Lee S., Lee D.Y., Choi D. Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration. Sci. Rep, 2023, vol. 13 (1), pp. 15461. DOI: 24.10.1038/s41598-023-42788-6
25. Goldštajn M.Š., Mikuš M., Ferrari F.A., Bosco M., Uccella S., Noventa M. et al. Effects of transdermal versus oral hormone replacement therapy in postmenopause: A systematic review. Arch. Gynecol. Obstet, 2023, vol. 307 (6), pp. 1727–1745. DOI: 25.10.1007/s00404-022-06647-5
26. Florio A.A., Graubard B.I., Yang B. et al. Oophorectomy and risk of non-alcoholic fatty liver disease and primary liver cancer in the clinical practice research datalink. Eur. J. Epidemiol, 2019, vol. 34 (9), pp. 871–878. DOI: 10.1007/s10654-019-00526-1
27. Yang J.D., Abdelmalek M.F., Guy C.D. et al. Patient sex, reproductive status, and synthetic hormone use associate with histologic severity of nonalcoholic steatohepatitis. Clin. Gastroenterol. Hepatol, 2017, vol. 15 (1), pp. 127–131. DOI: 27.10.1016/j.cgh.2016.07.034
28. Stanczyk F.Z., Hapgood J.P., Winer S., Mishell D.R. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocrine Rev, 2013, vol. 34 (2), pp. 171–208. DOI: 28.10.1210/er.2012-1008
29. Di Stasi V., Contaldo A., Birtolo L.I., Shahini E. Interplay of cardiometabolic syndrome and biliary tract cancer: a comprehensive analysis with gender-specific insights. Cancers, 2024, vol. 16 (19), p. 3432. DOI: 29.10.3390/cancers16193432
30. Saddick M.N., Salim S., Shahid I. et al. Association between estrogen and gallstones: a mechanistic insight. Discover Public Health, 2024, vol. 21 (1), p. 113. DOI: 30.10.1186/s12982-024-00232-8
31. DeLeon C., Wang H.H., Gunn J., Wilhelm M., Cole A., Arnett S. et al. A novel GPER antagonist protects against the formation of estrogen-induced cholesterol gallstones in female mice. J. Lipid Res, 2020, vol. 61 (5), pp. 767–777. DOI: 31.10.1194/jlr.RA119000592
32. Bofill Rodriguez M., Yong L.N., Mirkov S., Bekos C., Lethaby A., Farquhar C. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst. Rev, 2025, vol. 11. Art. CD004143. DOI: 32.10.1002/14651858.CD004143.pub6
33. Ding G.-J., Jiang W., Lyu J.-Q., Ma J., Chen G.-C., Li F.-R. et al. Menopausal characteristics and hormone replacement therapy in relation to long-term risk of cholecystectomy in women. Front. Med, 2024, vol. 11, p. 1446271. DOI: 33.10.3389/fmed.2024.1446271
34. Jackson S.S., Graubard B.I., Gabbi C. et al. Association with menopausal hormone therapy and asymptomatic gallstones in US women in the third National Health and Nutrition Examination Study. Sci. Rep, 2024, vol. 14, p. 191. DOI: 34.10.1038/s41598-023-50509-2
35. Lee S.R., Cho M.K., Cho Y.J., Chun S., Hong S.H., Hwang K.R. et al. The 2020 menopausal hormone therapy guidelines. J. Menopausal Med, 2020, vol. 26 (2), pp. 69–98. DOI: 10.6118/jmm.20000
36. Buyeverov A.O., Smetnik A.A. Review of data on the impact of menopausal hormone therapy on the risk of developing cholelithiasis: results of a cohort study based on the health insurance database in South Korea. Akusherstvo i ginekologiya: novosti, mneniya, obucheniye, 2025, vol. 13, no. 2, pp. 122–136 (in Russ.). DOI: 36.10.33029/2303-9698-2025-13-2-122-136
37. Mayev I.V., Reshetnyak V.I. The mechanism of development of laboratory signs in primary biliary cholangitis and their diagnostic value. Effektivnaya farmakoterapiya, 2024, no. 18 (in Russ.), available at: https://cyberleninka.ru/article/n/mehanizm-razvitiya-laboratornyh-priznakov-pri-pervichnom-biliarnom-holangite-i-ih-diagnosticheskoe-znachenie(accessed on: 10.02.2026).
38. Zu Y., Yang J., Zhang C., Liu D. The pathological mechanisms of estrogen-induced cholestasis: current perspectives. Front. Pharmacol, 2021, vol. 12. Art. 761255. DOI: 10.3389/fphar.2021.761255
39. Madyanov I.V. Madyanova T.S. Menopausal hormone therapy for certain diseases of the therapeutic profile. Lechashchiy vrach, 2018, no. 3, pp. 50–54 (in Russ.).
40. Danford C.J., Trivedi H.D., Papamichael K., Tapper E.B., Bonder A. Osteoporosis in primary biliary cholangitis. World J. Gastroenterol, 2018, vol. 24 (31), pp. 3513–3520. DOI: 10.3748/wjg.v24.i31.3513
41. Danford C.J., Ezaz G., Trivedi H.D., Tapper E.B., Bonder A. The pharmacologic management of osteoporosis in primary biliary cholangitis: a systematic review and meta-analysis. J. Clin. Densitometry, 2020, vol. 23 (2), pp. 223–236. DOI: 10.1016/j.jocd.2019.05.003
42. Wang C.H., Lin R.C., Hsu H.Y., Tseng Y.T. Hormone replacement therapy is associated with reduced hepatocellular carcinoma risk and improved survival in postmenopausal women with hepatitis B: A nationwide long-term population-based cohort study. PLoS ONE, 2022, vol. 17 (7). Art. e0271790. DOI: 42.10.1371/journal.pone.0271790